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ABSTRACT 
Daunorubicin-GnRH-III bioconjugates have recently been developed as drug delivery systems 
with potential applications in targeted cancer chemotherapy. In order to improve their 
biochemical properties, several strategies have been pursued: (1) incorporation of an 
enzymatic cleavable spacer between the anticancer drug and the peptide-based targeting 
moiety, (2) peptide modification by short chain fatty acids or (3) attachment of two anticancer 
drugs to the same GnRH-III derivative. Although these modifications led to more potent 
bioconjugates, a decrease in their solubility was observed. Here we report on the design, 
synthesis and biochemical characterization of daunorubicin-GnRH-III bioconjugates with 
increased solubility, which could be achieved by incorporating oligoethylene glycol-based 
spacers in their structure. First, we have evaluated the effect of an oligoethylene glycol-based 
spacer on the solubility, enzymatic stability/degradation, cellular uptake and in vitro cytostatic 
effect of a bioconjugate containing only one daunorubicin attached through a GFLG 
tetrapeptide spacer to the GnRH-III targeting moiety. Thereafter, more complex compounds 
containing two copies of daunorubicin, GFLG spacers as well as Lys(nBu) in position 4 of 
GnRH-III were synthesized and biochemically characterized. Our results indicated that all 
synthesized oligoethylene glycol-containing bioconjugates had higher solubility in cell culture 
medium than the unmodified analogs. They were degraded in the presence of rat liver 
lysosomal homogenate leading to the formation of small drug containing metabolites. In the 
case of bioconjugates containing two copies of daunorubicin, the incorporation of 
oligoethylene glycol-based spacers led to increased in vitro cytostatic effect on MCF-7 human 
breast cancer cells.  
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INTRODUCTION 
Tumor targeting with peptides whose receptors are highly expressed on cancer cells is a 
modern and promising oncological approach, which may significantly decrease the side 
effects of classical chemotherapy. The application of such peptides as carriers/targeting 
moieties in a bioconjugate with chemotherapeutic agents can provide a specific receptor-
mediated drug delivery. Furthermore, the slow release of the drug or the intracellular 
formation of active drug containing metabolites may enhance the therapeutic window of the 
bioconjugates, in comparison with the administration of free chemotherapeutic agents [1-4].  
A promising targeting moiety to be used for the preparation of anticancer drug delivery 
systems is the hypothalamic decapeptide gonadotropin-releasing hormone (GnRH). In 
particular, the natural isoform GnRH-III (<EHWSHDWKPG-NH2, where <E is pyroglutamic 
acid) isolated from the sea lamprey (Petromyzon marinus) [5, 6] is suitable for this purpose, 
owing to its binding to the GnRH receptors [7], found to be highly expressed on various types 
of cancer cells [3, 8]. Moreover, GnRH-III exerts a direct antiproliferative effect on cancer 
cells [9, 10] and has lower endocrine activity than human GnRH [3, 11-13]. Furthermore, it 
has been shown that the modification of lysine in position 8 of GnRH-III did not result in the 
loss of its biological properties [9]; thus, in our previous studies, the side chain of 8Lys was 
employed as a conjugation site for the formation of symmetric GnRH-III dimers and 
anticancer drug-peptide bioconjugates [14, 15]. A panel of anticancer drug-GnRH-III 
derivative bioconjugates was designed, synthesized and biochemically characterized in our 
laboratories [16-21]. The most promising compounds contained daunorubicin (Dau) attached 
via oxime linkage to the ε-amino group of 8Lys, either directly or through a GFLG 
tetrapeptide spacer cleavable by cathepsin B, an enzyme known to be overexpressed in cancer 
cells. These bioconjugates, GnRH-III[8Lys(Dau=Aoa)] and GnRH-III[8Lys(Dau=Aoa-
GFLG)] (Aoa = aminooxyacetyl), exerted significant in vitro and in vivo antitumor effect, 
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they were stable in human serum for at least 24 h and degraded in the presence of rat liver 
lysosomal homogenates [17, 18]. According to mass spectrometric analysis, no free Dau was 
released, indicating increased enzymatic and chemical stability of the oxime linkage. The 
smallest drug containing metabolites produced by lysosomal enzymes that were able to bind 
in vitro to DNA contained daunorubicin connected to an aminooxyacetylated amino acid [18]. 
On the basis of these initial results, we further aimed to develop bioconjugates with enhanced 
enzymatic stability, in particular against digestive enzymes such as chymotrypsin, with 
increased cellular uptake and antitumor activity. We found that the replacement of 4Ser by N-
Me-Ser, Lys(Ac) or Lys acylated with short chain fatty acids significantly improved the 
stability against chymotrypsin and the cellular uptake of oxime bond-linked Dau-GnRH-III 
derivative bioconjugates [16, 20]. Regarding their antiproliferative effect, the bioconjugate 
containing 4Lys acylated with butyric acid was the most potent one in breast and colon cancer 
cells [16]. Moreover, we have shown that on castration resistant prostate cancer cells, the 
bioconjugate modified in position 4 by Lys(Ac), GnRH-III[4Lys(Ac), 8Lys(Dau=Aoa)], as 
well as the parent one, GnRH-III[8Lys(Dau=Aoa)], were rapidly internalized and exerted an 
antiproliferative effect by inducing apoptosis. This effect was specific, since it was abrogated 
by simultaneous treatment of the cells with a GnRH antagonist. Furthermore, after GnRH-
receptor silencing, the antitumor activity of the bioconjugates was abolished, indicating that 
the effect of daunorubicin-GnRH-III bioconjugates on cancer cells was mediated by type I 
GnRH receptor [22].  
Another drug design strategy, which led to bioconjugates with enhanced antitumor 
activity, was the replacement of 4Ser by Lys, followed by the attachment of two identical 
(e.g., Dau) or different chemotherapeutic agents (e.g., Dau and methotrexate) to both 4Lys and 
8Lys of the same targeting moiety. In another version of ”multi-drug” containing 
bioconjugates, two chemotherapeutic agents were attached to both α- and ε-amino groups of 
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an additional Lys attached to the side chain of 8Lys. Most of these compounds showed higher 
in vitro cytostatic effect and uptake into cancer cells, as well as increased enzymatic stability 
than the bioconjugates containing only one anticancer drug [19, 23]. However, the acylation 
of lysine in position 4 with fatty acids, the incorporation of a second anticancer drug in a 
bioconjugate, as well as the presence of a hydrophobic GFLG tetrapeptide spacer led to 
decreased solubility of the bioconjugates in aqueous buffers and cell culture media. 
It has previously been shown that the addition of an ethylene glycol-based spacer may 
result in cytotoxic bioconjugates with elevated solubility [24-26] or increased stability in 
circulation, allowing a stable accumulation in the tumor [27]. Thus, the incorporation of an 
oligoethylene glycol-based spacer may also provide increased solubility to oxime bond-linked 
Dau-GnRH-III derivative bioconjugates.  
On the basis of these previous findings, in the study reported here we aimed to investigate 
the effect of an oligoethylene glycol-based spacer on the solubility and biochemical properties 
(i.e., enzymatic stability/degradation, in vitro cytostatic effect) of (1) a bioconjugate in which 
the anticancer drug daunorubicin was attached via oxime bond, through a GFLG tetrapeptide 
spacer, to the GnRH-III targeting moiety, and of (2) bioconjugates containing two molecules 
of daunorubicin attached to a GnRH-III derivative in which 4Ser was replaced by Lys(nBu). In 
the latter bioconjugates, a GFLG spacer was incorporated or not between the anticancer drug 
and GnRH-based targeting moiety.  
Our results indicate that appropriate oligoethylene glycol derivatives may enhance not 
only the solubility, but also the in vitro cytostatic effect of daunorubicin-GnRH-III derivative 
bioconjugates, in particular of compounds containing two Dau molecules. Moreover, the 
incorporation of several structural and functional elements in a bioconjugate is a promising 
strategy that may result in increased antitumor activity. 
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MATERIALS AND METHODS 
Chemicals 
Amino acid derivatives, Fmoc-8-amino-3.6-dioxaoctanoic-acid (Fmoc-EG2) and Rink-
Amide MBHA resin were purchased from Iris Biotech GmbH (Marktredwitz, Germany), 
while Rink-Amide ChemMatrix resin was from PCAS BioMatrix Inc. (Quebec, Canada). 
Benzotriazol-1-yloxytrispyrrolidinophosphonium-hexafluoro-phosphate (PyBOP), bis-Boc-
aminooxyacetic acid (bis-Boc-Aoa-OH), Rink-Amide MBHA resin and Fmoc-12-amino-
4,7,10-trioxadodecanoic acid (Fmoc-EG1) were obtained from NovaBiochem (Läufelfingen, 
Switzerland). Aminooxyacetic acid, scavengers, coupling agents and cleavage reagents 
(N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uranium-hexafluoro-phosphate (HBTU), 1-
hydroxybenzotriazole hydrate (HOBt), N,N′-diisopropylcarbodiimide (DIC), 
triisopropylsilane (TIS), piperidine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 
trifluoroacetic acid (TFA)), diisopropylethylamine (DIPEA), acetic anhydride (Ac2O), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), n-butyric anhydride) were 
from Sigma-Aldrich Kft (Budapest, Hungary). Ethanol and diethyl ether were Riedel deHäen 
products (Seelze, Germany). Dimethylformamide (DMF), dichloromethane (DCM) and 
diethyl ether were purchased from Molar Chemicals Kft (Budapest, Hungary). Acetonitrile 
(MeCN) for HPLC and 4-methylmorpholine (NMM) were obtained from Sigma-Aldrich Kft. 
(Budapest, Hungary). Daunorubicin hydrochloride was a gift from IVAX (Budapest, 
Hungary). 
All reagents and solvents were of analytical grade or highest available purity. 
 
Synthesis of oxime bond-linked GnRH-III[
8
Lys(Dau=Aoa-GFLG)] (1) and GnRH-
III[
8
Lys(Dau=Aoa-GFLG-EG1) (2) bioconjugates 
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The synthesis of GnRH-III[8Lys(Dau=Aoa-GFLG) (1) was carried out by a combination 
of solid phase peptide synthesis and chemical ligation in solution (oxime bond formation) as 
previously reported [18]. The bioconjugate containing an ethylene glycol-based spacer (EG1 = 
12-amino-4,7,10-trioxadodecanoic acid), oxime bond-linked GnRH-III[8Lys(Dau=Aoa-
GFLG-EG1)] (2), was prepared by a slightly different procedure. The aminooxyacetylated 
derivative of GnRH-III (<EHWSHDWK(Aoa-GFLG-EG1)PG-NH2, where <E is 
pyroglutamic acid and Aoa is aminooxyacetyl) was prepared manually by solid phase peptide 
synthesis using Fmoc/tBu chemistry on a Rink-Amide MBHA resin (0.36 mmol/g coupling 
capacity). The following Fmoc-protected amino acid derivatives were used: Fmoc-Gly-OH, 
Fmoc-Pro-OH, Fmoc-Lys(Mtt)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-
His(Trt)-OH and Fmoc-Ser(tBu)-OH. The protocol of the synthesis was as follows: (i) DMF 
washing (4 × 1 min), (ii) Fmoc deprotection with 2% DBU, 2% piperidine in DMF (3 + 7 
min), (iii) DMF washing (10 × 1 min), (iv) coupling of 5 equiv Fmoc-protected amino 
acid:PyBOP:NMM (1:1:2 v/v/v) in DMF (60 min), (v) DMF washing (4 × 1 min). After the 
synthesis of protected linear GnRH-III derivative, the Mtt-protecting group was removed from 
the ε-NH2 group of 
8Lys with 2% TFA in DCM (6 x 5 min), followed by the coupling of 
Fmoc-EG1. After Fmoc deprotection with 2% DBU, 2% piperidine in DMF, the synthesis 
continued with building the GFLG tetrapeptide spacer and coupling of 5 equiv of bis-Boc-
Aoa-OH, after preactivation with PyBOP/NMM (1 h coupling time). The aminooxyacetylated 
peptides were cleaved from the resin using a mixture of 95% TFA, 2.5% TIS and 2.5% water 
(v/v/v) in the presence of 10 equiv of free aminooxyacetic acid as a “carbonyl capture” 
reagent [28], for 2.5 h at room temperature, precipitated with ice-cold diethyl ether, washed 
three times with diethyl ether and solubilized in 100% acetic acid prior to freeze drying. The 
crude products were purified by semipreparative RP-HPLC and chemically characterized by 
analytical HPLC and mass spectrometry. 
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The conjugation of daunorubicin to the aminooxyacetylated GnRH-III derivatives was 
carried out in 0.2 M sodium acetate buffer, pH 5.0, at a peptide concentration of 10 mg/mL. 
Daunorubicin was used in 30% excess compared to the aminooxyacetylated derivatives of 
GnRH-III. The reaction mixtures were stirred at room temperature for 24 hours and then 
subjected to RP-HPLC purification. The purified bioconjugates were characterized by 
analytical RP-HPLC and mass spectrometry. 
 
Synthesis of GnRH-III[
4
Lys(nBu), 
8
Lys(Dau=Aoa-X-Y-Lys(Dau=Aoa-X-Y))] bioconjugates 
(where X=Ø, Y= Ø (3); X=GFLG, Y= Ø (4); X=Ø, Y=EG2 (5); X=GFLG, Y=EG2 (6))  
The [4Lys]-GnRH-III derivatives acylated with n-butyric acid in position 4 and elongated 
with an additional lysine residue on the side chain of 8Lys were prepared by solid phase 
peptide synthesis according to Fmoc/tBu chemistry. The branched peptide derivatives were 
modified on the resin with aminooxyacetic acid attached to both α- and ε-amino groups of the 
additional Lys, either directly or through (i) an oligoethylene glycol-based spacer (EG2=8-
amino-3,6-dioxaoctanoic acid), and/or (ii) a GFLG tetrapeptide. The following Fmoc-
protected amino acid derivatives were used: Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-Lys(Mtt)-
OH, Fmoc-Trp-OH, Fmoc-Asp(OtBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Lys(Dde)-OH and 
Fmoc-Lys(Fmoc)-OH. 
After completing the synthesis of the protected decapeptide, the Dde-protecting group of 
the ε-NH2 group of 
4Lys was removed by 4% hydrazine in DMF (12 x 5 min); after that, the 
n-butyration of the free ε-NH2 group was achieved using 3 equiv n-butyric anhydride : DIEA 
(1:1, mol/mol) for 2 h. After removing the Mtt-protecting group from the ε-NH2 group of 
8Lys 
(2% TFA, 2% TIS (triisopropylsilane) in DCM for 6 × 5 min), the Fmoc-Lys(Fmoc)-OH was 
coupled to the resulting free amino group. Then, the Fmoc protecting groups were removed 
and further modifications were separately performed. In one case, Fmoc-EG2 was coupled to 
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both α- and ε-amino groups of lysine and then the resin was divided into two portions. To one 
of them, bis-Boc-Aoa-OH was coupled for 2 h using DIC/HOBt coupling reagents (3 equiv 
each to the amino groups) (in the case of compound 5). In the case of compound 6, two copies 
of the GFLG tetrapeptide spacer were built and then bis-Boc-Aoa-OH was coupled as 
described before. In the other two cases, the bis-Boc-Aoa-OH was attached directly (for 
compound 3) to the amino groups of Lys in the branch or to those of the incorporated GFLG 
spacers (for compound 4), as mentioned above. 
The aminooxyacetylated peptides were cleaved from the resin, worked-up, purified and 
chemically characterized as mentioned above and after that the conjugation of daunorubicin 
was performed. The reaction mixtures were subjected to RP-HPLC purification and the 
purified bioconjugates were characterized by analytical RP-HPLC and mass spectrometry. 
 
High performance liquid chromatography (HPLC) 
The bioconjugates 1 and 2 were purified on a SpectraSystem (Thermo Fisher Scientific, 
Dreieich, Germany) using a semipreparative Vydac C18 column (250 mm x 10 mm, 10 µm 
silica, 300 Å pore size). Linear gradient elution (0 min 20% B; 5 min 20% B; 55 min 70% B) 
with eluent A (0.1% TFA in water) and eluent B (0.1% TFA in MeCN-H2O (80:20, v/v)) was 
used at a flow rate of 4 mL/min.  
Analytical RP-HPLC was performed on an UltiMate 3000 (Dionex, Idstein, Germany) 
using a Hypersil GOLD C18 column (250 mm x 4.6 mm) with 5 µm silica (300 Å pore size) 
as a stationary phase (Thermo Fischer, Dreieich, Germany). A linear gradient elution (0 min 0 
% B; 5 min 0 % B; 55 min 100 % B) was used.  
Daunorubicin-GnRH-III derivative bioconjugates 3-6 were purified on a KNAUER 2501 
HPLC system (H. Knauer, Bad Homburg, Germany) using a semipreparative Phenomenex 
Luna C18 column (250 mm x 10 mm) with 10 µm silica (100 Å pore size) (Torrance, CA). 
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Linear gradient elution (0 min 20% B; 5 min 20% B; 50 min 100% B) with eluent A (0.1% 
TFA in water) and eluent B (0.1% TFA in MeCN-H2O (80:20, v/v)) was used at a flow rate of 
4 mL/min.  
Analytical RP-HPLC of bioconjugates 3-6 was performed on a KNAUER 2501 HPLC 
system using a Phenomenex Luna C18 column (250 mm x 4.6 mm) with 5 µm silica (100Å 
pore size) as a stationary phase. Linear gradient elution (0 min 0% B; 5 min 0% B; 50 min 
90% B or 0 min 0% B; 2 min 0% B; 25 min 100% B) at a flow rate of 1 mL/min with the 
same eluents described above.  
 
Mass spectrometry (MS) 
Electrospray (ESI)-mass spectrometric analyses were carried out on an Esquire 3000+ ion 
trap mass spectrometer (Bruker Daltonics, Bremen, Germany). Spectra were acquired in the 
50 - 2500 m/z range. Samples were dissolved in a mixture of 50% methanol, 48% water and 
2% acetic acid.  
Liquid chromatography-mass spectrometry (LC-MS) was carried out on an Esquire 3000+ 
ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an Agilent 
1100 HPLC system (Agilent, Waldbronn, Germany) and a diode array detector. Peptides were 
separated on a Vydac MS C18 column (150 mm x 1 mm; 300 Å, 3 µm) using a linear gradient 
from 90% eluent A (0.1% formic acid in water (v/v)) and 10% eluent B (0.1% formic acid in 
acetonitrile (v/v)) to 70% eluent B over 60 minutes and a flow rate of 50 µL/min. Spectra 
were recorded in positive ion mode in the 50 - 2500 m/z range. 
 
Solubility determination of the bioconjugates using an HPLC-based approach 
The solubility of the bioconjugates in DMEM cell culture medium was determined as 
follows: a 2 mM aqueous solution of each bioconjugate was diluted with cell culture medium 
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to obtain a 100 µM concentration. This solution was incubated for 15 min at room 
temperature and then centrifuged for 15 min at 13000 rpm. From the obtained supernatant, an 
appropriate volume, which should contain 30 µg of bioconjugate - assuming that it would 
have been completely soluble at a concentration of 100 µM - was taken and diluted to a 
volume of 500 µL with 0.1% TFA in water (HPLC eluent A). A reason for diluting the 
solution with eluent A was also to adjust the pH to 2.5, before analyzing the sample by 
analytical RP-HPLC. In the case of bioconjugates 1 and 2, the analyses were performed on an 
UltiMate 3000 HPLC system (Dionex, Idstein, Germany) as described above. The 
bioconjugates containing two copies of daunorubicin were analyzed on an Exformma EX1600 
HPLC system (Wincom, Shanghai, China) using a Zorbax SB-C18 column (150 x 4.6 mm, 5 
µm silica, pore size 80 Å) and the following linear gradient: 0 min 0 % B; 2 min 0 % B; 22 
min 90% B (eluent A: 0.1% TFA in water; eluent B: 0.1% TFA in acetonitrile:water (80:20, 
v/v)). HPLC profiles of the eluents and of cell culture medium were also recorded, in order to 
assign and subtract all signals that were not given by the bioconjugates. Based on standard 
curves obtained with different amounts of bioconjugates dissolved in water, the solubility of 
each bioconjugate in cell culture medium was assessed by extrapolation. 
 
Stability of GnRH-III[(
8
Lys(Dau=Aoa-GFLG-EG1)] bioconjugate in human serum 
The stability of GnRH-III[(8Lys(Dau=Aoa-GFLG-EG1)] in 90% human serum was 
determined as previously reported for GnRH-III[(8Lys(Dau=Aoa-GFLG)] [18]. Briefly, the 
bioconjugate was first dissolved in water to obtain a stock solution of 100 µM concentration, 
which was added to human serum, so that the final bioconjugate concentration was 10 µM. 
The mixture was incubated at 37°C and aliquots were taken after 5 min and 24 h. After 
quenching the reactions with acetic acid, the large human serum proteins were removed using 
Microcon centrifugal filter devices with 10 kDa cut-off (Millipore Corporation, Bedford, MA, 
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USA), followed by the LC-MS analysis of the lower molecular weight fraction. Two control 
experiments were also performed: (1) 90% human serum and (2) an aqueous solution of the 
bioconjugate (c = 10 µM) were incubated at 37°C and aliquots taken after 5 min and 24 h 
were analyzed by LC-MS. 
 
Degradation of oxime bond-linked Daunorubicin-GnRH-III derivative bioconjugates in the 
presence of rat liver lysosomal homogenate 
The rat liver lysosomal homogenate was prepared as previously described [16,18-21]. The 
protein concentration was determined by Pierce BCA (bicinchoninic acid) protein assay, 
according to the manufacturer’s protocol (ThermoFisher Scientific, Rockford, IL,) and it was 
17.4 µg/µL. The bioconjugates were dissolved in 0.2 M NaOAc, pH 5.0, at a concentration of 
0.1 µg/µL and then the rat liver lysosomal homogenate was added (bioconjugate : lysosomal 
homogenate ratio = 1:1, w/w). The reaction mixtures were incubated at 37°C and aliquots of 
50 µL were taken after 5 min, 1 h, 2 h, 4 h, 6 h, 8 h and 24 h. The reactions were quenched by 
adding 5 µL of acetic acid, followed by freezing the samples and storage at -28ºC until further 
analysis. Each aliquot was then subjected to LC-MS analysis. Control experiments were 
performed by incubating the bioconjugate solutions (0.1 µg/µL in 0.2 M sodium acetate 
buffer, pH 5.0) at 37°C for 24 h, followed by LC-MS analysis, in order to assess their 
chemical stability under these experimental conditions. 
 
Cells 
MCF-7 (ATCC:HTB-22) human breast adenocarcinoma cells were maintained in DMEM 
(Sigma Ltd., St. Louis, MO) medium containing 10% FCS (fetal calf serum, Sigma Ltd.), L-
glutamine (2 mM), gentamicin (160 µg/mL), 1 mM pyruvate and non-essential amino acids 
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(Sigma Ltd.). The cell culture was maintained at 37°C in a humidified atmosphere with 5% 
CO2. 
 
Cellular uptake of bioconjugates 1 and 2 determined by flow cytometry  
To determine the cellular uptake of bioconjugates 1 and 2, MCF-7 human breast cancer 
cells were plated at a number of 1 x 105 cells per well on 24-well plates in 1 mL complete 
medium. After 24 h incubation at 37°C, cells were centrifuged for 5 min at 1000 rpm and the 
supernatant was removed. Thereafter, 250 µL of bioconjugate solutions (in serum-free 
medium) were added onto the cells in the 0.16 µM to 100 µM concentration range. Control 
cells were treated with serum-free medium. Cells were incubated with bioconjugate solutions 
at 37°C for 6 h. After that, the solutions were removed from the cells, 100 µL trypsin were 
added per well and incubated for 10 min at 37°C. After adding 900 µL of HPMI (glucose, 
NaHCO3, NaCl, HEPES, KCl, MgCl2, CaCl2, Na2HPO4·2H2O) supplemented with 10% FCS, 
cells were transferred to FACS tubes and centrifuged for 5 min at 1000 rpm. After that, the 
supernatant was removed and the cells were resuspended in 500 µL HPMI. Fluorescence 
intensity of the cells was determined by flow cytometry (BD LSR II, BD Bioscience, San 
Jose, CA, USA). Data were analyzed with the FACSDiVa software. 
 
In vitro cytostatic effect of the bioconjugates determined by MTT assay 
The in vitro cytostatic effect of the bioconjugates was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT assay). One day before 
the treatment, 5 x 103 MCF-7 cells per well were plated on 96-well plates. After 24 h 
incubation at 37°C, the cells were treated for 6 h with the bioconjugates used in the 0.256-100 
µM concentration range. The solutions were prepared in serum-free medium. Cells treated for 
6 h with serum-free medium were used as a control. After treatment and incubation, cells were 
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washed twice with serum-free medium and cultured in serum containing medium for 72 h. On 
the fourth day, the MTT assay was performed. MTT was added to each well (final 
concentration: 367 µg/mL) and during 3.5 h incubation at 37°C, purple crystals were formed 
by mitochondrial dehydrogenase enzyme present in the living cells. After that, cells were 
centrifuged for 5 min at 2000 rpm and the supernatant was removed. The crystals were 
dissolved in 100 µL DMSO and the optical density (OD) was determined at λ = 540 and 620 
nm using an ELISA Reader (Labsystems MS reader, Helsinki, Finland). OD620 was subtracted 
from OD540 and the percentage of cytostasis was calculated using the following equation: 
Cytostasis % = [1-(ODtreated/ODcontrol)] × 100 
where ODtreated and ODcontrol correspond to the optical densities of treated and control cells, 
respectively. Cytostasis % was plotted as a function of concentration, fitted to a sigmoid curve 
and the 50% inhibitory concentration (IC50) value was determined from these curves. 
 
RESULTS AND DISCUSSION 
Oligoethylene glycol-modified bioconjugate containing only one daunorubicin attached 
through a GFLG tetrapeptide spacer to the GnRH-III targeting moiety 
Synthesis and chemical characterization of GnRH-III based bioconjugates containing only 
one daunorubicin  
The syntheses of bioconjugates 1 (GnRH-III[8Lys(Dau=Aoa-GFLG)] and 2 (GnRH-
III[8Lys(Dau=Aoa-GFLG-EG1)]; EG1 is 4,7,10-trioxadodecanoic acid) containing only one 
Dau (Figure 1) were carried out by a combination of solid phase peptide synthesis (Fmoc/tBu 
chemistry) and chemical ligation in solution (oxime bond formation), as previously published 
[18]. Both bioconjugates were purified by semipreparative RP-HPLC and then the purified 
compounds were characterized by analytical RP-HPLC and mass spectrometry (bioconjugate 
1: Rt = 31.5 min; MWcalc / MWexp = 2216.3 / 2215.9; bioconjugate 2: Rt = 31.7 min; MWcalc / 
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MWexp = 2419.6 / 2419.1; Figures S1 and S2 in Supporting Information). As previously 
reported, fragmentation of the glycosidic bonds during electrospray-mass spectrometric (ESI-
MS) analysis could be observed, resulting in the loss of daunosamine moiety (-129, -147) [16, 
18]. These fragments were labeled in all mass spectra with an asterisk. 
 
Solubility of bioconjugates 1 and 2 in cell culture medium determined by an HPLC-based 
approach 
Solubility determinations are generally based on weight measurements [29], which are not 
precise in the case of low amounts of sample. To evaluate the influence of the oligoethylene 
glycol-based spacer on the solubility of oxime bond-linked Dau-GnRH-III derivative 
bioconjugates in cell culture medium, an RP-HPLC based approach was established in the 
present study. This method was based on AUC determinations and it only required a standard 
curve, which was first recorded using different concentrations of a particular bioconjugate 
dissolved in water. Thereafter, a sample which should contain a certain amount of 
bioconjugate (30 µg, assuming that it would completely be soluble) was analyzed (Figure S3 
in Supporting Information).  
Our results indicated that the incorporation of an oligoethylene glycol-based spacer led to 
a bioconjugate 2 with significantly higher solubility than 1 (78.8% vs. 42.5%, Table 1) in cell 
culture medium.  
 
Enzymatic stability/degradation of bioconjugates 1 and 2 in human serum and lysosomal 
homogenate 
An important feature of targeted cancer chemotherapeutics is their stability in human 
serum until they reach the site of action, since premature drug release would lead to 
undesirable side effects. On the other hand, bioconjugates need to be processed in the cells, 
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particularly in lysosomes, in order to release the free drug or to generate drug-containing 
metabolites displaying antitumor activity.  
Degradation of bioconjugate 1 in the presence of rat liver lysosomal homogenate has 
previously been reported [18] and results are summarized in Figure 1A and Table S1. The 
degradation of bioconjugate 2 was investigated by LC-MS, which led to the identification of 
several cleavage sites, both within the GFLG spacer and the GnRH-III sequence (Figure 1B 
and Table S1).  
In agreement with our previous findings, no free daunorubicin was detected by LC-MS, 
indicating substantial chemical and enzymatic stability of the oxime bond [16, 18]. The 
smallest drug containing metabolite generated in the case of both bioconjugates in the 
presence of lysosomal enzymes and identified by mass spectrometry was Dau=Aoa-Gly-OH 
(m/z 658.1 (1+)) (Figure S4 in Supporting Information). We have previously shown that this 
drug containing metabolite was able to bind to DNA in vitro, thus providing an explanation 
for the antitumor activity of the bioconjugates. Taken together, these results allow concluding 
that the oligoethylene glycol-based spacer did not influence the enzymatic degradation of the 
bioconjugate, in particular when an enzymatic cleavable GFLG tetrapeptide spacer was 
incorporated in its structure. 
Furthermore, the effect of the oligoethylene glycol spacer on the stability of bioconjugate 
2 in human serum was also investigated. We have previously reported that various oxime 
bond-linked Dau-GnRH-III derivative bioconjugates developed in our laboratories, including 
compound 1, were stable in human serum for at least 24 h [18, 20]. In the present study, the 
influence of the oligoethylene glycol-based spacer on the stability of bioconjugate 2 in human 
serum was determined by LC-MS. After 5 min and 24 h incubation at 37°C, aliquots were 
taken from the reaction mixture and subjected to MS analysis, which indicated that the 
incorporation of an oligoethylene glycol-based spacer in the structure of the bioconjugate did 
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not influence its stability in human serum, in comparison with that of compound 1; intact 
bioconjugate 2 was detectable by mass spectrometry even after 24 h incubation with human 
serum (Figure 2A). As described in the experimental section, two control experiments were 
performed, in which both 90% human serum and an aqueous solution of the bioconjugate 
were incubated at 37°C and analyzed by LC-MS, in order to facilitate the interpretation of 
mass spectrometric data and to also assess the chemical stability of the bioconjugate (Figures 
2B and 2C). 
 
Cellular uptake of bioconjugates 1 and 2 determined by flow cytometry  
Based on the fluorescence properties of daunorubicin [18], the uptake of bioconjugates 1 
and 2 by MCF-7 human breast cancer cells was determined by flow cytometry, at different 
bioconjugate concentrations (between 0.16 and 100 µM). As shown in Figure 3, both 
compounds were taken up by MCF-7 cells in a concentration dependent manner; however, no 
significant differences could be observed in the entire concentration range. Very slight 
differences could be determined at a concentration of 4 µM, the oligoethylene glycol 
containing compound being characterized by an elevated cellular uptake (Dau positive MCF-7 
cells: 8.6% vs. 6.0%).  
 
Cytostatic effect of bioconjugates 1 and 2 
The in vitro cytostatic effect of bioconjugates 1 and 2 was evaluated on MCF-7 human 
breast cancer cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay. The IC50 values were determined on the basis of the dose-response curves (Figure S5 in 
Supporting Information) and indicated no significant difference between the in vitro cytostatic 
effect of both bioconjugates (IC50 = 3.6 ± 0.5 µM for bioconjugate 1 and 5.1 ± 0.5 for 
bioconjugate 2, respectively). Compared to free daunorubicin (IC50 = 0.4 ± 0.1 µM) [21], both 
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bioconjugates exerted lower in vitro cytostatic effect. This result is in agreement with our 
previous studies and can be explained by the mechanisms of cellular uptake, namely passive 
diffusion in the case of free Dau vs. receptor-mediated endocytosis, which is followed by 
intracellular processing of the bioconjugates. In the particular case of oxime bond-linked Dau-
GnRH-III bioconjugates 1 and 2, no free Dau release was observed in the presence of 
lysosomal homogenates; Dau=Aoa-Gly-OH was the smallest drug containing metabolite 
identified by LC-MS. This might provide an additional explanation for the different in vitro 
cytostatic effect of free and conjugated Dau. The advantage of oxime bond-linked Dau-
GnRH-III bioconjugates over the application of free Dau can be seen in vivo. In a recent 
study, we have shown that bioconjugate 1 exerted significant tumor growth inhibitory effect 
on colon carcinoma bearing mice, while no signs of toxicity were detected on healthy mice 
[17, 30]. Moreover, compared to free Dau, the bioconjugate had broader therapeutic window. 
Taken together, these results support the concept of targeted cancer chemotherapy, namely 
increased selectivity and decreased peripheral toxicity of conjugated anticancer drugs. 
 
Oligoethylene glycol modified GnRH-III based bioconjugates containing two copies of 
daunorubicin 
Synthesis and chemical characterization of GnRH-III based bioconjugates containing two 
copies of daunorubicin  
We have previously shown that the attachment of two Dau molecules to the same GnRH-
III based targeting moiety resulted in bioconjugates that exerted higher in vitro cytostatic 
effect than the parent bioconjugate GnRH-III[8Lys(Dau=Aoa)], in which Dau was attached 
via oxime bond to the native GnRH-III. We have also found that the replacement of 4Ser by 
Lys(nBu) in the GnRH-III sequence led to a bioconjugate with increased antitumor activity 
than GnRH-III[8Lys(Dau=Aoa)]. On the basis of these results, in the study reported here we 
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aimed to combine the structural elements mentioned above in a single bioconjugate; i.e., the 
attachment of two Dau units to a GnRH-III derivative modified in position 4 by Lys(nBu). In 
another bioconjugate, a GFLG tetrapeptide spacer was also incorporated between Dau and the 
targeting moiety, with the aim of facilitating intracellular drug release. Since these 
modifications may lead to decreased solubility of the biocojugates, two compounds containing 
oligoethylene glycol-based spacers were also synthesized and characterized, with special 
emphasis on the influence of the oligoethylene glycol on their solubility, enzymatic 
degradation and antitumor activity. In this case, a slightly different oligoethylene glycol 
derivative was used; namely, 8-amino-3,6-dioxaoctanoic acid, which may provide increased 
solubility and is more affordable than 12-amino-4,7,10-trioxadodecanoic acid. For the 
synthesis of bioconjugates 3-6, the lysine residues in positions 4 and 8 were orthogonally 
protected (position 4: Lys(Dde), position 8: Lys(Mtt)) in order to selectively perform their 
deprotection and further modifications (Scheme 1). The cleavage of the Dde protecting group 
and the acylation of 4Lys with butyric acid were carried out prior to the removal of Mtt under 
acidic conditions, followed by the attachment of a further lysine derivative (Fmoc-Lys(Fmoc)-
OH), which provided two attachment sites. After removing the Fmoc groups, both α- and ε-
amino groups of Lys in the branch were modified by aminooxyacetylation, thus allowing the 
attachment of two Dau copies via oxime bond (in order to prepare bioconjugate 3). For the 
preparation of compounds 4-6, the α- and ε-amino groups of Lys in the branch were used for 
building the GFLG spacers or for the attachment of oligoethylene glycol derivatives, followed 
by aminooxyacetylation. All compounds were cleaved from the resin with a mixture of TFA 
and appropriate scavengers. Daunorubicin was conjugated to the aminooxyacetylated GnRH-
III derivatives by oxime ligation, which was carried out under slightly acidic conditions (pH 
5.0). After purification by semipreparative RP-HPLC, bioconjugates 3-6 were characterized 
by analytical RP-HPLC and MS (bioconjugate 3: Rt = 28.5 min; MWcalc / MWexp = 2661.8 / 
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2662.8; bioconjugate 4: Rt = 33.1 min; MWcalc / MWexp = 3410.8 / 3411.3; bioconjugate 5: Rt 
= 27.0 min; MWcalc / MWexp = 2952.2 / 2953.0; bioconjugate 6: Rt = 30.7 min; MWcalc / 
MWexp = 3701.0 / 3701.4; Figures S6 - S9 in Supporting Information). Their structures are 
represented in Figure 4. 
 
Solubility determination of bioconjugates 3-6 using an HPLC-based approach 
The solubility of bioconjugates 3-6 containing two Dau copies was determined by the 
HPLC-based approach described above. As summarized in Table 2, incorporation of the 
oligoethylene glycol based spacer significantly improved the solubility of the compounds, 
from 16.4% (bioconjugate 3) to 45.1% (bioconjugate 5) and from 1.6% (bioconjugate 4) to 
10.6% (bioconjugate 6), respectively. 
 
Enzymatic degradation of bioconjugates 3-6 in the presence of lysosomal enzymes 
The degradation of butyrated bioconjugates 3-6 in the presence of lysosomal enzymes was 
determined by LC-MS, as described above. Cleavage sites were identified within the GFLG 
spacer (bioconjugates 4 and 6) and GnRH-III sequence (bioconjugates 3-6), as well. 
Furthermore, the isopeptide bond between 8Lys and the additional Lys in the braches was 
cleaved in bioconjugates 3-5. In agreement with our previous findings reported for compound 
GnRH-III[4Lys(nBu), 8Lys(Dau=Aoa)] [16], the fragment detected at m/z 581.3 (1+) was 
assigned to peptide  <EHWK-OH, indicating cleavage of the amide bond between the 4Lys 
and the fatty acid (Figure 4). The release of free butyric acid in cancer cells may play an 
important role in inducing an apoptotic effect [31-33]. The formation of the smallest drug 
containing fragment was strongly dependent on the structure of the bioconjugates. The 
recorded mass spectra of bioconjugates 3-6 incubated with the lysosomal homogenate are 
shown in the Supporting Information, Figures S10-S13 and the identified fragments are 
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summarized in Table S2. The smallest Dau containing metabolites identified by MS were as 
follows: bioconjugate 3: [Dau=Aoa-Lys(Dau=Aoa)]-OH detected at m/z 655.8 (2+), 
bioconjugate 4: Dau=Aoa-Gly-OH detected at m/z 658.1 (1+)), bioconjugate 5: Dau=Aoa-
EG2-OH detected at m/z 745.1 (1+), bioconjugate 6: Dau=Aoa-Gly-OH detected at m/z 658.1 
(1+)). 
We have previously shown that both H-Lys(Dau=Aoa)-OH and Dau=Aoa-Gly-OH could 
efficiently bind DNA in vitro, this result providing an explanation for the cytostatic effect and 
mechanism of action of the bioconjugate [18]. From the bioconjugate 3, in which Dau=Aoa 
was directly attached to both amino groups of the additional Lys coupled to 8Lys of GnRH-III, 
a fairly large fragment was identified as being the smallest drug containing metabolite 
produced by lysosomal enzymes. This finding may explain its lower cytostatic effect (Table 
3). In bioconjugate 5, Dau=Aoa is connected to the ethylene glycol moiety and Dau=Aoa-
EG2-OH was detected by mass spectrometry as the smallest drug containing metabolite. 
 
In vitro cytostatic effect of bioconjugates 3-6 
The in vitro cytostatic effect of bioconjugates 3-6 was determined on MCF-7 human 
breast cancer cells by MTT assay (Table 3). The incorporation of the GFLG tetrapeptide 
spacer and/or oligoethylene glycol moiety led to an increased antiproliferative effect of 
bioconjugates 4-6 (IC50 = 1.3 ± 0.4 µM, 0.9 ± 0.4 µM and 0.5 ± 0.1 µM, respectively) 
compared to compound 3 (IC50 = 7.7 ± 0.4 µM). The latter analog was also the least sensitive 
to degradation in the presence of lysosomal homogenate, resulting in the largest Dau 
containing metabolite. To elucidate whether the increased cytostatic effect is derived from the 
elevated solubility of the oligoethylene glycol containing bioconjugates or/and from the type 
of released metabolites, further studies are necessary.  
Taken together, the results reported here indicate that bioconjugates 5 and 6, which 
contain two copies of Dau and of an oligoethylene glycol moiety, had the highest in vitro 
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cytostatic effect on MCF-7 human breast cancer cells. By comparing bioconjugates 3 and 4, 
we found that the incorporation of a GFLG spacer led to elevated antitumor activity, a result 
that may be explained by the size of the drug containing metabolites produced in the presence 
of lysosomal enzymes. On the basis of these results, it can be concluded that incorporation of 
several structural and functional elements in a bioconjugate may provide improved 
physicochemical and biological properties. 
 
CONCLUSIONS 
In the present work, GnRH-III and its derivative modified in position 4 by Lys(nBu) were 
employed as targeting moieties to which one or two copies of Dau were attached via oxime 
bond, leading to the formation of drug delivery systems with potential applications in targeted 
cancer chemotherapy. In order to facilitate the drug release, a cathepsin B-cleavable GFLG 
tetrapeptide spacer was also incorporated in some of the bioconjugates. Furthermore, 
oligoethylene glycol-based spacers were used with the primary goal of improving their 
solubility and biological properties (e.g., the antiproliferative activity).  
In the case of a bioconjugate containing only one Dau attached through a GFLG spacer to 
the native GnRH-III, the incorporation of an oligoethylene glycol spacer led to enhanced 
solubility in cell culture medium, as determined by an HPLC-based approach. However, no 
significant influence of the oligoethylene glycol moiety on the in vitro stability/degradation, 
cellular uptake and cytostatic effect of the bioconjugate was observed. 
The incorporation of oligoethylene glycol spacers in the structure of bioconjugates 
containing two Dau copies attached to GnRH-III[4Lys(nBu)] led to elevated solubility as well. 
The degradation of these “multi-drug” bioconjugates in the presence of rat liver lysosomal 
homogenate was investigated by LC-MS, which indicated that the formation of the smallest 
drug containing fragments was strongly dependent on bioconjugate structure. Furthermore, 
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the compounds containing the oligoethylene glycol moiety showed enhanced cytostatic effect 
on MCF-7 human breast cell lines.  
Taken together, these results suggest that appropriate oligoethylene glycol derivatives may 
enhance not only the solubility, but also the in vitro cytostatic effect of Dau-GnRH-III 
derivative bioconjugates developed as drug delivery systems. In a long term perspective, the 
incorporation of several structural and functional elements in a bioconjugate is a promising 
strategy that may result in increased antitumor activity of anticancer drug-peptide 
bioconjugates, with potential applications in targeted cancer chemotherapy. 
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Additional Supporting Information may be found in the online version of this article. 
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Figure legends 
Fig. 1. Structure representation of bioconjugates 1 and 2. Cleavage sites identified by mass 
spectrometry after incubation with rat liver lysosomal homogenates are marked by 
arrows. 
Fig. 2. Stability of GnRH-III[8Lys(Dau=Aoa-GFLG-EG1)] (2) in human serum: (A) ESI-ion 
trap mass spectrum recorded after 24 h of incubation of the bioconjugate with 90% 
human serum. ESI-ion trap mass spectrum was averaged over the chromatographic 
window where the compounds eluted. The m/z values corresponding to the intact 
bioconjugate were marked bold. (B) Human serum control and (C) Aqueous solution 
of GnRH-III[8Lys(Dau=Aoa-GFLG-EG1)] after 24 h of incubation at 37°C. 
Fig. 3. Cellular uptake of GnRH-III[8Lys(Dau=Aoa-GFLG)] and GnRH-III[8Lys(Dau=Aoa-
GFLG-EG1)] bioconjugates by MCF-7 human breast cancer cells. 
Fig 4. Structure representation of bioconjugates 3-6. Cleavage sites that were identified by 
mass spectrometry after their incubation with rat liver lysosomal homogenates were 
marked by arrows. 
 
Scheme 1. Outline of the synthesis of bioconjugate 5. 
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Table 1. Solubility in cell culture medium of oxime bond-linked daunorubicin-GnRH-III 
derivative bioconjugates 1 and 2 
Solubility  Compound 1 Compound 2 
in µg 12.7 23.6 
in µmol 0.00575 0.00977 
in % 42.5 78.8 
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Table 2. Solubility in cell culture medium of bioconjugates 3-6 containing two copies of 
Daunorubicin 
Solubility  Compound 3  Compound 4  Compound 5  Compound  6 
in µg 8.7 1.1 26.7 7.9 
in µmol 0.00327 0.0033 0.00903 0.00213 
in % 16.4 1.6 45.1 10.6 
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Table 3. In vitro cytostatic effect of bioconjugates 3-6 on MCF-7 human breast cancer cells 
Compound 
Nr. 
Compound Code 
Cytostasis  
MCF-7 
IC50 (µM) 
3 GnRH-III[
4
Lys(nBu),
8
Lys(Dau=Aoa-Lys(Dau=Aoa))]  7.7 ± 0.4 
4 
GnRH-III[
4
Lys(nBu),
8
Lys(Dau=Aoa-GFLG-Lys(Dau=Aoa-
GFLG))]  
1.3 ± 0.4 
5 GnRH-III[
4
Lys(nBu),
8
Lys(Dau=Aoa-EG2-Lys(Dau=Aoa-EG2))]  0.9 ± 0.4 
6 
GnRH-III[
4
Lys(nBu),
8
Lys(Dau=Aoa-GFLG-EG2-Lys(Dau=Aoa-
GFLG-EG2))]  
0.5 ± 0.1 
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Structure representation of bioconjugates 1 and 2. Cleavage sites identified by mass spectrometry after 
incubation with rat liver lysosomal homogenates are marked by arrows.  
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Stability of GnRH-III[8Lys(Dau=Aoa-GFLG-EG1)] (2) in human serum: (A) ESI-ion trap mass spectrum 
recorded after 24 h of incubation of the bioconjugate with 90% human serum. ESI-ion trap mass spectrum 
was averaged over the chromatographic window where the compounds eluted. The m/z values 
corresponding to the intact bioconjugate were marked bold. (B) Human serum control and (C) Aqueous 
solution of GnRH-III[8Lys(Dau=Aoa-GFLG-EG1)] after 24 h of incubation at 37°C.  
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Stability of GnRH-III[8Lys(Dau=Aoa-GFLG-EG1)] (2) in human serum: (A) ESI-ion trap mass spectrum 
recorded after 24 h of incubation of the bioconjugate with 90% human serum. ESI-ion trap mass spectrum 
was averaged over the chromatographic window where the compounds eluted. The m/z values 
corresponding to the intact bioconjugate were marked bold. (B) Human serum control and (C) Aqueous 
solution of GnRH-III[8Lys(Dau=Aoa-GFLG-EG1)] after 24 h of incubation at 37°C.  
254x338mm (300 x 300 DPI)  
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Cellular uptake of GnRH-III[8Lys(Dau=Aoa-GFLG)] and GnRH-III[8Lys(Dau=Aoa-GFLG-EG1)] bioconjugates 
by MCF-7 human breast cancer cells.  
254x190mm (300 x 300 DPI)  
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Structure representation of bioconjugates 3-6. Cleavage sites that were identified by mass spectrometry 
after their incubation with rat liver lysosomal homogenates were marked by arrows.  
254x190mm (300 x 300 DPI)  
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Structure representation of bioconjugates 3-6. Cleavage sites that were identified by mass spectrometry 
after their incubation with rat liver lysosomal homogenates were marked by arrows.  
254x190mm (300 x 300 DPI)  
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Structure representation of bioconjugates 3-6. Cleavage sites that were identified by mass spectrometry 
after their incubation with rat liver lysosomal homogenates were marked by arrows.  
254x190mm (300 x 300 DPI)  
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Outline of the synthesis of bioconjugate 5.  
254x190mm (300 x 300 DPI)  
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